Etiology of Persistent Microalbuminuria in Nigeria
尼日利亚持续性微量白蛋白尿的病因学
基本信息
- 批准号:10325071
- 负责人:
- 金额:$ 61.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:APOL1 geneAcquired Immunodeficiency SyndromeAddressAdultAgeAlbuminsAlbuminuriaAngiotensin ReceptorAngiotensin-Converting Enzyme InhibitorsBacterial InfectionsBiological MarkersBlood PressureCD14 geneCD4 Lymphocyte CountCardiovascular DiseasesCardiovascular systemCaringCellsCreatinineCytomegalovirusDataData StoreDevelopmentDiabetes MellitusDiseaseEarly DiagnosisEndotheliumEnrollmentEtiologyExposure toFibrin fragment DFilaria bancroftiFumaratesGeneral PopulationHIVHIV SeronegativityHIV SeropositivityHepatitis BHepatitis CHepatitis C co-infectionHigh PrevalenceHypertensionInflammationInflammatoryInterleukin-6KidneyKidney DiseasesLeadLisinoprilLoa loaLow PrevalenceMeasurementMedicalMicroalbuminuriaMonitorMorbidity - disease rateMycobacterium tuberculosisNigeriaOnchocerca volvulusOrganParasitic infectionParticipantPersonsPharmaceutical PreparationsPhasePlasmodium falciparumPopulationPrevalenceRegimenRenin-Angiotensin-Aldosterone SystemRiskRisk FactorsRisk ReductionRoleSchistosomaSickle Cell TraitSiteSmokingSpecimenStrongyloides stercoralisT-Cell ActivationTNFR-Fc fusion proteinTNFRSF1A geneTeaching HospitalsTenofovirTestingTuberculosisViralVirus Diseasesantiretroviral therapycardiovascular risk factorcigarette smokingco-infectioncohortcomorbidityeligible participantendothelial dysfunctionexperiencehigh riskimmune activationinflammatory markermacroalbuminuriamortalitynephrotoxicitynon-diabeticnormotensiveprehypertensionprospectiverandomized placebo controlled trialrisk variantscreeningsextherapy developmentvirology
项目摘要
ABSTRACT: Microalbuminuria is an independent risk factor for cardiovascular and kidney disease and a
predictor of end organ damage, both in the general population and in persons living with HIV (PLWH).
Microalbuminuria, defined as an albumin-to-creatinine ratio (uACR) 30-300 mg/g, can signify either early
glomerular damage or microvascular endothelial dysfunction and has been used in the early detection of
kidney disease. Microalbuminuria is also an important risk factor for mortality in PLWH treated with
antiretroviral therapy (ART), likely as a marker for inflammation and endothelial activation. In the ongoing
Renal Risk Reduction (R3) study in Nigeria, 36.9% had microalbuminuria confirmed by two measurements 4-
8 weeks apart, and 2.8% had macroalbuminuria (uACR >300 mg/g). The median duration on ART was 9 years
[IQR 6,12], median CD4 cell count was 482 cells/mm3 [IQR 324–661], 95.7% were virally suppressed, and
12.7% had stage 1 or 2 hypertension (22.1% with pre-hypertension). In contrast, other traditional risk factors
for albuminuria and kidney disease, including diabetes (2.1%), APOL1 high-risk genotype (6.2%), and smoking
(5%) were uncommon. A significant proportion (~59%) were currently receiving potentially nephrotoxic ARV
medications, specifically tenofovir disoproxil fumarate. Lastly, endemic co-infections, including viral (e.g.
hepatitis B and C, Cytomegalovirus), parasitic (e.g. Plasmodium falciparum, Schistosoma species,
Strongyloides stercoralis, Onchocerca volvulus, Loa loa, Wuchereria bancrofti), and bacterial (Mycobacterium
tuberculosis) co-infections, may be potential contributors to albuminuria. To better understand this, we plan to
test the following overarching hypothesis: Hypertension, immune activation from co-infections, and
cumulative, long-term exposure to potentially nephrotoxic ARV medications contribute to the high
rates of microalbuminuria in these ART-experienced adults. To test this hypothesis, we propose the
following Specific Aims:
1) To compare the prevalence of albuminuria and established kidney disease risk factors in a large cohort
of PLWH to age- and sex-matched HIV-negative adults presenting for routine medical care at the Aminu
Kano Teaching Hospital in Kano, Nigeria. We will leverage data and stored specimens from 2500 R3
participants who were previously screened for microalbuminuria and will prospectively enroll an additional
300 PLWH recently initiated on ART (≤ 12 months) and 750 age- and sex-matched HIV-negative adults.
2) To determine the role that hypertension and other comorbid medical conditions (e.g. sickle cell trait or
disease, immune activation/inflammation from parasitic infestations and tuberculosis, and exposure to
potentially nephrotoxic ARV medications), have on the risk for development of albuminuria. We will enroll
1000 HIV-positive, ART-treated normoalbuminuric adults and 500 HIV-negative normoalbuminuric adults
from Aim 1 and follow them longitudinally for three years.
摘要:微量白蛋白尿是心血管和肾脏疾病的独立危险因素,
终末器官损伤的预测因子,无论是在普通人群和艾滋病毒感染者(PLWH)。
微量白蛋白尿,定义为白蛋白与肌酐比值(uACR)30-300 mg/g,可表示早期
肾小球损伤或微血管内皮功能障碍,并已用于早期检测
肾病微量白蛋白尿也是PLWH患者死亡的一个重要危险因素,
抗逆转录病毒治疗(ART),可能作为炎症和内皮激活的标志物。正在进行的
在尼日利亚进行的肾脏风险降低(R3)研究中,36.9%的患者经两次测量证实存在微量白蛋白尿4-
间隔8周,2.8%有大量白蛋白尿(uACR >300 mg/g)。接受抗逆转录病毒治疗的中位时间为9年
[IQR 6,12],中位CD 4细胞计数为482个细胞/mm 3 [IQR 324-661],95.7%的病毒受到抑制,
12.7%有1或2期高血压(22.1%有高血压前期)。相比之下,其他传统风险因素
蛋白尿和肾脏疾病,包括糖尿病(2.1%),APOL 1高风险基因型(6.2%)和吸烟
(5%)不常见。很大一部分人(约59%)目前正在接受可能具有肾毒性的抗逆转录病毒治疗
药物,特别是富马酸替诺福韦酯。最后,地方性合并感染,包括病毒性(例如,
B和C型肝炎,巨细胞病毒),寄生虫(例如恶性疟原虫,血吸虫属,
粪类圆线虫、盘尾丝虫、Loa loa、班氏吴策线虫)和细菌(分枝杆菌
结核病)合并感染,可能是蛋白尿的潜在贡献者。为了更好地理解这一点,我们计划
测试以下总体假设:高血压,合并感染的免疫激活,
累积的,长期暴露于潜在的肾毒性抗逆转录病毒药物有助于高
这些ART经验丰富的成人中微量白蛋白尿的发生率。为了验证这一假设,我们提出了
具体目标:
1)在一个大型队列中比较蛋白尿的患病率和已确定的肾脏疾病危险因素
在阿米努医院接受常规医疗护理的年龄和性别匹配的HIV阴性成年人中,
位于尼日利亚卡诺的卡诺教学医院。我们将利用来自2500 R3的数据和储存的标本
既往接受过微量白蛋白尿筛查的受试者,
300名最近开始接受抗逆转录病毒治疗(≤ 12个月)的艾滋病毒感染者和750名年龄和性别匹配的艾滋病毒阴性成人。
2)确定高血压和其他共病疾病(如镰状细胞性状或
疾病、寄生虫感染和结核病引起的免疫激活/炎症,以及暴露于
潜在的肾毒性抗逆转录病毒药物),有发生蛋白尿的风险。我们将招收
1000例HIV阳性、ART治疗的正常白蛋白尿成人和500例HIV阴性的正常白蛋白尿成人
从目标1开始,纵向跟踪他们三年。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Muktar Hassan Aliyu其他文献
Muktar Hassan Aliyu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Muktar Hassan Aliyu', 18)}}的其他基金
Vanderbilt-Nigeria Biostatistics Training Program (VN-BioStat)
范德比尔特-尼日利亚生物统计学培训计划(VN-BioStat)
- 批准号:
10594548 - 财政年份:2022
- 资助金额:
$ 61.65万 - 项目类别:
Vanderbilt-Nigeria Biostatistics Training Program (VN-BioStat)
范德比尔特-尼日利亚生物统计学培训计划(VN-BioStat)
- 批准号:
10470510 - 财政年份:2022
- 资助金额:
$ 61.65万 - 项目类别:
Etiology of Persistent Microalbuminuria in Nigeria
尼日利亚持续性微量白蛋白尿的病因学
- 批准号:
10432130 - 财政年份:2021
- 资助金额:
$ 61.65万 - 项目类别:
Vanderbilt-Nigeria Research Administration and Management Training Program (V-RAMP)
范德比尔特-尼日利亚研究行政和管理培训计划 (V-RAMP)
- 批准号:
10374937 - 财政年份:2021
- 资助金额:
$ 61.65万 - 项目类别:
Vanderbilt-Nigeria Research Administration and Management Training Program (V-RAMP)
范德比尔特-尼日利亚研究行政和管理培训计划 (V-RAMP)
- 批准号:
10240150 - 财政年份:2021
- 资助金额:
$ 61.65万 - 项目类别:
Etiology of Persistent Microalbuminuria in Nigeria
尼日利亚持续性微量白蛋白尿的病因学
- 批准号:
10617771 - 财政年份:2021
- 资助金额:
$ 61.65万 - 项目类别:
Vanderbilt-Nigeria Research Administration and Management Training Program (V-RAMP)
范德比尔特-尼日利亚研究行政和管理培训计划 (V-RAMP)
- 批准号:
10584603 - 财政年份:2021
- 资助金额:
$ 61.65万 - 项目类别:
Vanderbilt-Nigeria Building Research Capacity in HIV and Non-communicable Diseases (NCDs) (V-BRCH)
范德比尔特-尼日利亚建设艾滋病毒和非传染性疾病 (NCD) 研究能力 (V-BRCH)
- 批准号:
10328263 - 财政年份:2020
- 资助金额:
$ 61.65万 - 项目类别:
Vanderbilt-Nigeria Building Research Capacity in HIV and Non-communicable Diseases (NCDs) (V-BRCH)
范德比尔特-尼日利亚建设艾滋病毒和非传染性疾病 (NCD) 研究能力 (V-BRCH)
- 批准号:
10542417 - 财政年份:2020
- 资助金额:
$ 61.65万 - 项目类别:
Optimal Management of HIV Infected Adults at Risk for Kidney Disease in Nigeria
尼日利亚有肾病风险的艾滋病毒感染者的最佳管理
- 批准号:
10255513 - 财政年份:2017
- 资助金额:
$ 61.65万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 61.65万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 61.65万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 61.65万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 61.65万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 61.65万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 61.65万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 61.65万 - 项目类别: